{
  "id": "5a723a652dc08e987e00000a",
  "type": "summary",
  "question": "Describe mechanism of action of Romosozumab.",
  "ideal_answer": "Romosozumab, a humanized monoclonal antibody that binds to sclerostin, prevents sclerostin from exerting this inhibitory effect. In the presence of romosozumab, the Wnt signaling pathway is activated leading to bone formation and bone mineral density gain. It is used for osteoporosis treatment.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28064540",
    "http://www.ncbi.nlm.nih.gov/pubmed/24665957",
    "http://www.ncbi.nlm.nih.gov/pubmed/28428078",
    "http://www.ncbi.nlm.nih.gov/pubmed/28246926",
    "http://www.ncbi.nlm.nih.gov/pubmed/27865001",
    "http://www.ncbi.nlm.nih.gov/pubmed/27569204",
    "http://www.ncbi.nlm.nih.gov/pubmed/26277199",
    "http://www.ncbi.nlm.nih.gov/pubmed/27487526",
    "http://www.ncbi.nlm.nih.gov/pubmed/28529724",
    "http://www.ncbi.nlm.nih.gov/pubmed/24835636",
    "http://www.ncbi.nlm.nih.gov/pubmed/28458516",
    "http://www.ncbi.nlm.nih.gov/pubmed/26451332"
  ],
  "snippets": [
    {
      "text": "Romosozumab, a monoclonal antibody that binds sclerostin, has a dual effect on bone by increasing bone formation and reducing bone resorption, and thus has favorable effects in both aspects of bone volume regulation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27487526",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Romosozumab is a humanized monoclonal antibody to sclerostin that binds to sclerostin, permitting the engagement of Wnt ligands with their co-receptors, resulting in an increase in bone formation and bone mineral density (BMD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28064540",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Romosozumab (Romo), a humanized sclerostin antibody, is a bone-forming agent under development for treatment of osteoporosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27865001",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment with sclerostin antibody (romosozumab) increases bone formation while reducing bone resorption, leading to increases in bone volume and bone mineral density. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28246926",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Romosozumab, a humanized monoclonal antibody that binds to sclerostin, prevents sclerostin from exerting this inhibitory effect. Therefore, in the presence of romosozumab, the Wnt signaling pathway is activated leading to bone formation and bone mineral density gain.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28458516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Romosozumab, a humanized monoclonal sclerostin antibody under development for the treatment of osteoporosis, has a unique mechanism of action on bone-increasing bone formation and decreasing bone resorption.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28428078",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Romosozumab, an anti-sclerosin antibody, and abaloparatide, a PTH-related peptide analog, are at present in advanced stages of clinical evaluation, so far demonstrating efficaciousness together with a favorable safety profile.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26277199",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Update on romosozumab : a humanized monoclonal antibody to sclerostin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Romosozumab, a humanized monoclonal antibody that binds to sclerostin, prevents sclerostin from exerting this inhibitory effect.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28458516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Romosozumab is a humanized immunoglobulin G2 monoclonal antibody that binds and blocks the action of sclerostin, a protein secreted by the osteocyte and an extracellular inhibitor of canonical Wnt signaling.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569204",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Romosozumab is a humanized monoclonal antibody to sclerostin that binds to sclerostin, permitting the engagement of Wnt ligands with their co-receptors, resulting in an increase in bone formation and bone mineral density (BMD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28064540",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "EXPERT OPINION Blocking sclerostin action with romosozumab is a promising new therapeutic approach to osteoanabolic therapy of osteoporosis; efficacy and safety data on large controlled studies are awaited.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AREAS COVERED Romosozumab is the first humanized monoclonal sclerostin antibody to be tested in clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Romosozumab is a humanized monoclonal antibody targeting sclerostin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24835636",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Romosozumab, an anti-sclerostin antibody, inhibits the action of sclerostin, a canonical Wnt signal inhibitor secreted from osteocytes, and enhances canonical Wnt signaling.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28529724",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A pharmacokinetic model with first-order absorption and dual elimination pathways was used to describe the kinetics of romosozumab, a monoclonal antibody (mAb) against sclerostin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26451332",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Similar to preclinical animal studies with sclerostin antibodies, initial clinical studies show that romosozumab increases bone formation and bone mineral density.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://meshb.nlm.nih.gov/record/ui?ui=D045504"
  ]
}